Lilly reports Phase IIIb data on Taltz and Zepbound combination

Phase 3positiveTaltzZepboundPositive

AI Analysis

Summary

Lilly reported Phase IIIb data demonstrating that combining Taltz and Zepbound produces greater alterations in immune and metabolic biomarkers compared to Taltz alone in patients with moderate-to-severe plaque psoriasis and obesity or overweight.

Clinical Trial Data

Phase

IIIb

Primary Endpoint

Met

Outcome Details

Combination of Taltz and Zepbound altered more immune and metabolic biomarkers than Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight

Importance:6/10

Sentiment:

0.60

combination therapypsoriasisobesitybiomarkersexploratory

Related Companies

$LLY

Read the original article

Published by Clinical Trials Arena on October 12, 2026 10:04 AM

Read Original